Alzamend Neuro (ALZN) Projected to Post Earnings on Monday

Alzamend Neuro (NASDAQ:ALZN) is anticipated to post its quarterly earnings results before the market opens on Monday, March 24th. Analysts expect Alzamend Neuro to post earnings of ($0.29) per share for the quarter.

Alzamend Neuro (NASDAQ:ALZN) last announced its quarterly earnings data on Monday, March 10th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.10. On average, analysts expect Alzamend Neuro to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Alzamend Neuro Trading Down 1.8 %

Shares of ALZN stock opened at $0.68 on Monday. Alzamend Neuro has a 1-year low of $0.64 and a 1-year high of $15.06. The firm’s 50-day simple moving average is $1.02 and its 200-day simple moving average is $1.36.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets dropped their target price on shares of Alzamend Neuro from $35.00 to $32.00 and set a “buy” rating for the company in a research report on Monday, December 16th.

About Alzamend Neuro

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.